| 货号 | 12328S |
| 供应商 | CST |
| 背景 | Sunitinib, also known as SU11248, is a multi-tyrosine kinase inhibitor widely known to target PDGFR, VEGFR, KIT, and FLT3, and therefore has both antitumor and antiangiogenic activities. Cellular phosphorylation assays show that sunitinib effectively inhibits ligand-dependent phosphorylation of these receptor tyrosine kinases in nanomolar concentrations and can also inhibit ligand-dependent cellular proliferation (1-3). Sunitinib displays greater than 10-fold selectively for PDGFRB and VEGFR over numerous other kinases, including EGFR, Cdk2, Met, IGF -1R, Abl, and src (2). Inhibition of CSF-1 (4) and RET (5) by sunitinib has also been observed. |
| 存放说明 | -20C |
| 参考文献 | 1 . Abrams, T.J. et al. (2003) Mol Cancer Ther 2, 471-8. 2 . Mendel, D.B. et al. (2003) Clin Cancer Res 9, 327-37. 3 . OFarrell, A.M. et al. (2003) Blood 101, 3597-605. 4 . Guo, J. et al. (2006) Mol Cancer Ther 5, 1007-13. 5 . Broutin, S. et al. (2011) Clin Cancer Res 17, 2044-54. |
Chemical structure of sunitinib.舒尼替尼的化学结构。 | |
Western blot analysis of extracts from NIH/3T3 cells, serum-starved overnight and untreated or treated with hPDGF-BB #8912 (100 ng/ml, 5 min) either with or without Sunitinib pre-treatment (2 hr) at the indicated concentrations, using Phospho-PDGF Receptor β (Tyr1009) (42F9) Rabbit mAb #3124 (upper) or PDGF Receptor β (28E1) Rabbit mAb #3169 (lower).Western blot方法检测NIH/3T3细胞提取物，细胞血清饥饿后，不处理或用hPDGF-BB #8912 (100 ng/ml, 5 min)处理，之前用或不用舒尼替尼在指定浓度预处理（2 hr），使用的抗体为Phospho-PDGF Receptor β (Tyr1009) (42F9) Rabbit mAb #3124 (上图)或PDGF Receptor β (28E1) Rabbit mAb #3169 (下图). |
